Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Abnormalities in Major Depression

Paul Carlson12 enrolled

Overview

Several lines of evidence support the existence of an underlying abnormality in brain energy metabolism may play a key role in the biology of mood disorders. The current study utilizes two distinct but complementary imaging techniques, fluorodeoxyglucose (FDG) positron emission tomography (PET) and multinuclear magnetic resonance spectroscopy (MRS), to better understand the nature of these metabolic abnormalities in major depressive disorder (MDD). The investigators hypothesize that individuals with depression will have increased metabolic activity as measured by PET in certain brain regions involved in mood regulation, but that this metabolic activity will be inefficient based on MRS findings. For this study, the investigators will study 10 medication-free, currently depressed participants with recurrent MDD, 10 depressed participants with recurrent MDD currently taking antidepressant medication, and up to 20 healthy control participants matched to depressed participants for age and gender. Depressed and healthy participants will each undergo one PET scan and one MRS scanning session.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Major Depressive Disorder

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Meet DSM-IV criteria for Major Depressive Disorder (MDD), Recurrent * Montgomery-Asberg Depression Rating Scale (MADRS) score \> 18 Exclusion Criteria: * Any coexisting psychiatric illness other than generalized anxiety disorder, panic disorder, or social/specific phobias * Any history of substance dependence * Substance abuse within the past 6 months * Significant risk of suicide, as defined by score \>4 on item 10 of the MADRS or in the clinical judgment of the study physician * Any significant medical or neurological condition which is likely to impact the central nervous system and/or affect the results of MRS or PET imaging * For the subset of unmedicated MDD patients, any psychotropic medications within 4 weeks prior to scanning. For the subgroup of medicated patients, they may be taking a stable dose (i.e., same dose for at least 4 weeks at the time of scanning) of standard antidepressant medications, but may not be taking any other psychotropic medication. * Inability to give informed consent * Contraindication to MRI (e.g., pacemaker, ferromagnetic implants in the body)

Outcomes

Primary Outcomes

high energy phosphate metabolites (Phosphocreatine (PCr)) as measured by magnetic resonance spectroscopy

relative concentration of Pcr

Time frame: cross-sectional

Secondary Outcomes

regional cerebral glucose metabolism, as measured by Positron Emission Tomography (PET)

binding potential of FDG

Time frame: cross-sectional

N-Acetyl-Aspartate (NAA) metabolite intensity, as measured by proton Magnetic Resonance Spectroscopy (MRS)

relative concentration of NAA

Time frame: cross-sectional

severity of depressive symptoms, as scored on the Montgomery-Asberg Depression Rating Scale (MADRS)

MADRS composite score

Time frame: cross-sectional

Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Abnormalities in Major Depression

Overview

Conditions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes